Christopher B. Cooper

2.2k total citations
47 papers, 1.3k citations indexed

About

Christopher B. Cooper is a scholar working on Molecular Biology, Infectious Diseases and Organic Chemistry. According to data from OpenAlex, Christopher B. Cooper has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 22 papers in Infectious Diseases and 16 papers in Organic Chemistry. Recurrent topics in Christopher B. Cooper's work include Tuberculosis Research and Epidemiology (22 papers), Cancer therapeutics and mechanisms (13 papers) and Biochemical and Molecular Research (5 papers). Christopher B. Cooper is often cited by papers focused on Tuberculosis Research and Epidemiology (22 papers), Cancer therapeutics and mechanisms (13 papers) and Biochemical and Molecular Research (5 papers). Christopher B. Cooper collaborates with scholars based in United States, New Zealand and United Kingdom. Christopher B. Cooper's co-authors include Anna M. Upton, William A. Denny, Scott G. Franzblau, Peter J. Choi, Brian D. Palmer, Hamish S. Sutherland, Amy S.T. Tong, Adrian Blaser, Daniel Conole and Zheming Ruan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Medicinal Chemistry and The Journal of Infectious Diseases.

In The Last Decade

Christopher B. Cooper

46 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher B. Cooper United States	21	684	522	502	287	107	47	1.3k
Adrian Blaser New Zealand	22	708 1.0×	465 0.9×	599 1.2×	283 1.0×	93 0.9×	30	1.3k
Giovanna Poce Italy	24	652 1.0×	634 1.2×	745 1.5×	421 1.5×	113 1.1×	54	1.7k
Hamish S. Sutherland New Zealand	15	517 0.8×	423 0.8×	411 0.8×	203 0.7×	87 0.8×	29	940
Giulio Cesare Porretta Italy	18	441 0.6×	490 0.9×	777 1.5×	310 1.1×	86 0.8×	29	1.3k
Vinayak Singh South Africa	21	559 0.8×	518 1.0×	263 0.5×	250 0.9×	101 0.9×	51	1.1k
Marion Flipo France	18	501 0.7×	299 0.6×	251 0.5×	158 0.6×	93 0.9×	30	962
Ill Young Lee South Korea	12	392 0.6×	454 0.9×	311 0.6×	323 1.1×	37 0.3×	18	938
Anna M. Upton United States	26	1.2k 1.8×	1.2k 2.3×	335 0.7×	693 2.4×	125 1.2×	41	2.0k
Rodrigo G. Ducati Brazil	16	590 0.9×	405 0.8×	112 0.2×	215 0.7×	105 1.0×	46	885
Nicolas Willand France	20	606 0.9×	411 0.8×	408 0.8×	193 0.7×	134 1.3×	58	1.2k

Countries citing papers authored by Christopher B. Cooper

Since Specialization

Citations

This map shows the geographic impact of Christopher B. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher B. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher B. Cooper more than expected).

Fields of papers citing papers by Christopher B. Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher B. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher B. Cooper. The network helps show where Christopher B. Cooper may publish in the future.

Co-authorship network of co-authors of Christopher B. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher B. Cooper. A scholar is included among the top collaborators of Christopher B. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher B. Cooper. Christopher B. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sutherland, Hamish S., Peter J. Choi, Guo‐Liang Lu, et al.. (2022). Synthesis and Structure–Activity Relationships for the Anti-Mycobacterial Activity of 3-Phenyl-N-(Pyridin-2-ylmethyl)Pyrazolo[1,5-a]Pyrimidin-7-Amines. Pharmaceuticals. 15(9). 1125–1125. 6 indexed citations

Thompson, Andrew M., P. D. T. O’Connor, Vanessa Yardley, et al.. (2021). Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility. ACS Medicinal Chemistry Letters. 12(2). 275–281. 10 indexed citations

Sutherland, Hamish S., Guo‐Liang Lu, Amy S.T. Tong, et al.. (2021). Synthesis and structure-activity relationships for a new class of tetrahydronaphthalene amide inhibitors of Mycobacterium tuberculosis. European Journal of Medicinal Chemistry. 229. 114059–114059. 9 indexed citations

Choi, Peter J., Guo‐Liang Lu, Hamish S. Sutherland, et al.. (2021). Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of Mycobacterium tuberculosis. Structural correction of reported N-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5-α]pyrimidin-7-amine. Tetrahedron Letters. 90. 153611–153611. 11 indexed citations

Ding, Jun, Qian Zhang, Xiaomei Wang, et al.. (2020). Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria. Molecules. 25(10). 2431–2431. 9 indexed citations

Lu, Guo‐Liang, Amy S.T. Tong, Daniel Conole, et al.. (2020). Synthesis and structure-activity relationships for tetrahydroisoquinoline-based inhibitors of Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry. 28(22). 115784–115784. 18 indexed citations

Thompson, Andrew M., P. D. T. O’Connor, Andrew J. Marshall, et al.. (2020). Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal. European Journal of Medicinal Chemistry. 209. 112914–112914. 17 indexed citations

Furkert, Daniel P., et al.. (2020). Synthetic approaches towards bedaquiline and its derivatives. Bioorganic & Medicinal Chemistry Letters. 30(12). 127172–127172. 20 indexed citations

Blaser, Adrian, Hamish S. Sutherland, Amy S.T. Tong, et al.. (2019). Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline. Bioorganic & Medicinal Chemistry. 27(7). 1283–1291. 40 indexed citations

10.

Sutherland, Hamish S., Amy S.T. Tong, Peter J. Choi, et al.. (2019). 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel. Bioorganic & Medicinal Chemistry. 27(7). 1292–1307. 81 indexed citations

11.

Sutherland, Hamish S., Amy S.T. Tong, Peter J. Choi, et al.. (2019). Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology. Bioorganic & Medicinal Chemistry. 28(1). 115213–115213. 29 indexed citations

12.

Sutherland, Hamish S., Amy S.T. Tong, Peter J. Choi, et al.. (2018). Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles. Bioorganic & Medicinal Chemistry. 26(8). 1797–1809. 59 indexed citations

13.

Choi, Peter J., Hamish S. Sutherland, Amy S.T. Tong, et al.. (2017). Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units. Bioorganic & Medicinal Chemistry Letters. 27(23). 5190–5196. 48 indexed citations

14.

Harikrishnan, Lalgudi S., Neelam Srivastava, David S. Nirschl, et al.. (2012). Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1). Bioorganic & Medicinal Chemistry Letters. 22(6). 2287–2290. 9 indexed citations

15.

Coxon, Geoffrey D., Christopher B. Cooper, Stephen H. Gillespie, & Timothy D. McHugh. (2012). Strategies and Challenges Involved in the Discovery of New Chemical Entities During Early-Stage Tuberculosis Drug Discovery. The Journal of Infectious Diseases. 205(suppl_2). S258–S264. 12 indexed citations

16.

Haque, Tasir S., Ving G. Lee, Ming Lei, et al.. (2010). Identification of potent 11mer Glucagon-Like Peptide-1 Receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs. Peptides. 31(5). 950–955. 14 indexed citations

17.

Cooper, Christopher B., et al.. (2006). For comparison: experience with a children’s obesity camp. Surgery for Obesity and Related Diseases. 2(6). 622–626. 18 indexed citations

18.

Dodd, Dharmpal S., Zheming Ruan, Christopher B. Cooper, et al.. (2005). Solid-Phase Synthesis of 5-Substituted Amino Pyrazoles. Journal of Combinatorial Chemistry. 7(4). 584–588. 13 indexed citations

19.

Helal, Christopher J., Mark A. Sanner, Christopher B. Cooper, et al.. (2004). Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer’s disease. Bioorganic & Medicinal Chemistry Letters. 14(22). 5521–5525. 86 indexed citations

20.

Cooper, Christopher B., et al.. (1979). Normally-Off GaAs FET Monolithic Technology.. Defense Technical Information Center (DTIC).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact